In CCl4-induced liver fibrosis mouse model, the VD60-treated group showed that a-SMA expression, TGF-β, and fibronectin mRNA levels, the fibrotic area, and hepatic hydroxyproline (HYP) deposition all decreased compared with the vehicle group, suggesting that VD60 could effectively ameliorate liver fibrosis. This evidence concerns the gene FN1 and Hepatic fibrosis.